Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures

Introduction

Program Overview

Thrombocytopenia: Clinical Significance

Factors Influencing the Decision to Treat Thrombocytopenia

Factors Influencing the Decision to Treat Thrombocytopenia (cont)

Treatment Options for Severe Thrombocytopenia

Platelet Transfusion

Normal Thrombopoiesis

Mechanism of Action of TPO RAs

TPO RAs

ELEVATE: Median Platelet Counts

ELEVATE: Incidence of Portal-Vein or Splanchnic-Vein Thrombosis

ELEVATE: Thrombotic Events in Patients Receiving Eltrombopag

ADAPT 1 and 2: Mean Platelet Counts

L-PLUS-2: Median Platelet Count

L-PLUS-2: Efficacy of Lusutrobopag

Lusutrombopag Safety: Pooled Analysis of 2 Phase 3 Trials

Use of TPO-RAs in Clinical Practice

Potential Role of Emerging TPO RAs

Program Summary

Abbreviations